PODCAST · health
Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)
by Annenberg Center for Health Sciences
Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.
-
4
Summary of Key Concepts
Subcutaneous ICI products may offer significant time savings for patients, caregivers, and health care facilities with shorter compounding, administration, and chair timeWith multiple ICI therapies now approved for subcutaneous injection and more under development, it is vital for institutions to develop interprofessional/multidisciplinary approaches and workflows to integrate novel therapies
-
3
Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems
SC products offer convenient and safe options for patients that may be preferred by patientsEffective communication among interprofessional, multidisciplinary team and patients/caregivers is crucial to success and streamlining processesTraining is required for providers and staff related to operational, clinical, and financial considerations of SC products
-
2
Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapiesPatients receiving SC ICI may experience mild injection site reactionsClinical guidelines (NCCN) recommend
-
1
Background of ICI & Highlights in Oncology
Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 yearsMultiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011Robust survival benefit seen with ICI across multiple tumor typesIV ICI therapy requires line access and creates increased chair timeSubcutaneous (SC) ICI options provide increased patient convenience and operational efficienciesSC products may increase nurse resources due to time spent administering
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.
HOSTED BY
Annenberg Center for Health Sciences
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) have?
Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) currently has 4 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) about?
Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists...
How often does Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) release new episodes?
Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) has 4 episodes. Check the episode list to see recent publication dates and frequency.
Where can I listen to Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)?
You can listen to Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)?
Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) is created and hosted by Annenberg Center for Health Sciences.
URL copied to clipboard!